BioSpace News Archive

908 Devices Reports First Quarter 2024 Financial Results and Updates 2024 Revenue Outlook.

Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that it will report first quarter financial results on May 14, 2024, prior to the market open.

Akero Therapeutics, Inc. today announced the appointment of Scott Gangloff as Chief Technology Officer.

Matinas BioPharma Holdings, Inc. announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, demonstrated efficacy compared with placebo in treating the pulmonary mucormycosis fungal infections Rhizopus delemar and M. circinelloides f. jenssenii in immunosuppressed mice.

Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed the topline analysis for the Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus vaccine candidate.

NeuroBo Pharmaceuticals, Inc. today announced the acceptance of poster presentations for its promising cardiometabolic assets, DA-1241 and DA-1726, at the EASL Congress 2024 and the American Diabetes Association.

Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., disclosed that under the recently announced U.S. strategic partnership agreement, Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® for Quallent Pharmaceuticals, in alignment with its U.S. commercialization agreement with Teva.

Foresee Pharmaceuticals, announced that the first subject has been dosed in its Phase 1 clinical trial of FP-020 in Australia.

Sphere Fluidics announced the appointment of Dale Levitzke as CEO with immediate effect, as Dr. Frank F. Craig, current CEO and co-founder, announces his retirement.

IN8bio, Inc. announced that the first patient in its Phase 2 clinical trial evaluating INB-400 in patients with newly diagnosed glioblastoma multiforme has been successfully dosed at the Cleveland Clinic in Ohio.